Dexcom G6 Finally Gets Official Classification
After nearly four years of treating the Dexcom glucose monitoring system as moderate-risk class II, the US FDA made the designation official.
You may also be interested in...
After more than three years of treating the Tandem Diabetes Care Control-IQ Technology system as moderate-risk class II, the US FDA has made the designation official. The classification will also apply to future similar devices.
The newly published data solidifies the G7 as an improvement over the G6 and supports its potential as a 14-day wearable.
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.